NASH - Nonalcoholic SteatohepatitisPhase 3NATiV3NCT04849728
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
A Phase 3 study testing IVA337 in people with NASH - Nonalcoholic Steatohepatitis, run by Inventiva Pharma at 459 sites in 24 countries.
Trial summary
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3 Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- NASH - Nonalcoholic Steatohepatitis
- What is being tested?
- IVA337
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,000 participants
- Where
- 459 sitesin 24 countries
- Study dates
- 19 Aug 2021to 30 Sep 2027
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, aged ≥18 years at the time of signing informed consent
- Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):
- Steatosis score ≥1
- Activity score: A3 or A4
- Fibrosis score: F2 or F3
- No qualitative change in dose for the drugs listed below:
Show all 12Show fewer
- Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months
- Vitamin E (if at a dose ≥400 IU/day): for at least 6 months
- Statins: for at least 3 months
- No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
- Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
- Negative serum pregnancy test at study Screening for females of childbearing potential confirmed by central laboratory. Females of childbearing potential must practice a consistent and proper use of highly effective method of contraception throughout the study and for 1 month after treatment discontinuation.
Who cannot join
- Liver-related:
- Documented causes of chronic liver disease other than NASH
- Histologically documented liver cirrhosis (fibrosis stage F4)
- History or current diagnosis of hepatocellular carcinoma (HCC)
- History of or planned liver transplant
- Positive human immunodeficiency virus (HIV) serology
Show all 30Show fewer
- ALT or AST >5 × ULN
- AST<0.6 ULN if the liver biopsy has to be performed in the scope of the study
- Abnormal synthetic liver function as defined by Screening central laboratory evaluation
- Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males
- Patient currently receiving any approved treatment for NASH or obesity
- Current or recent history (<5 years) of significant alcohol consumption
- Treatment with drugs that may cause non-alcoholic fatty liver disease (NAFLD) administered for at least 2 weeks within 12 months prior to qualifying liver biopsy
- Glycaemia related:
- HbA1c >9% at Screening
- Diabetes mellitus other than type 2
- Current treatment with insulin
- Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.
- Obesity related:
- Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy.
- Cardiovascular related:
- History of heart failure with reduced left ventricular ejection fraction (LVEF)
- Atrial fibrillation requiring anticoagulation
- Unstable heart failure
- Uncontrolled hypertension at Screening (values >160/100 mm Hg)
- General safety:
- Women currently breastfeeding
- Previous exposure to lanifibranor
- Participation in any clinical trial investigational medicinal product/device within 3 months from Screening or 5 half-lives from Screening, whichever is longer
- Concomitant treatment with PPAR-alpha agonists (fibrates)
Trial locations and contacts
459 sites in 24 countries.
459 sites in 24 countries
United States194 sites
Southwest Gastroenterology Associates
Albuquerque, New Mexico, 87109
Texas Clinical Research Institute
Arlington, Texas, 76012
Digestive Healthcare of Georgia
Atlanta, Georgia, 30309
Accelemed Research Institute
Austin, Texas, 78745
Mercy Medical Center - Mcauley Plaza
Baltimore, Maryland, 21202
The Johns Hopkins Hospital
Baltimore, Maryland, 21287
Objective Health - Birmingham Gastroenterology Associates
Birmingham, Alabama, 35209
Massachusetts General Hospital
Boston, Massachusetts, 02114
Boston Medical Center
Boston, Massachusetts, 02118
Beth Israel Deaconess Medical Center - Liver Center
Boston, Massachusetts, 02215
Synergy Healthcare
Bradenton, Florida, 34208
Florida Research Institute
Bradenton, Florida, 34209
South Texas Research Institute - Brownsville
Brownsville, Texas, 78520
State University of New York - University at Buffalo
Buffalo, New York, 14203
University of Vermont Medical Center
Burlington, Vermont, 05401
Fomatmedicalresearch
Camarillo, California, 93011
Digestive Disease Associates - Catonsville
Catonsville, Maryland, 21228
Velocity Clinical Research - Austin
Cedar Park, Texas, 78613
The Institute For Liver Health - Chandler
Chandler, Arizona, 85224-5688
Medical University of South Carolina
Charleston, South Carolina, 29425
Charlotte Gastroenterology and Hepatology - Randolph Road Office
Charlotte, North Carolina, 28207
University of Virginia Health System
Charlottesville, Virginia, 22903
Clinical Research Institute of Michigan
Chesterfield, Michigan, 48047
Galen Research
Chesterfield, Missouri, 63005
Chevy Chase Clinical Research
Chevy Chase, Maryland, 20815
Northwestern University
Chicago, Illinois, 60611
University of Chicago
Chicago, Illinois, 60611
GW Research
Chula Vista, California, 91910
Velocity Clinical Research, Chula Vista
Chula Vista, California, 91911
Consultants for Clinical Research - Montgomery Office
Cincinnati, Ohio, 45249
Tampa Bay Medical Research
Clearwater, Florida, 33761
Gastro Florida
Clearwater, Florida, 33762
University Hospitals Case Medical Center
Cleveland, Ohio, 44106
Heartland Medical Research
Clive, Iowa, 50325
Oracle Clinical Research
College Park, Georgia, 30349
Gastrointestinal (GI) Associates L.L.P.
Columbia, Missouri, 65201
IACT Health
Columbus, Georgia, 31904
The Ohio State University
Columbus, Ohio, 43201
Aventiv Research - Columbus
Columbus, Ohio, 43213
Centricity (Aventiv) Research - Columbus
Columbus, Ohio, 43213
ARcare Center for Clinical Research - Conway
Conway, Arkansas, 72032
Hi Tech and Global Research, LLC
Coral Gables, Florida, 33134
JY Research Institute Inc.
Cutler Bay, Florida, 33189
Top Medical Research
Cutler Bay, Florida, 33189
The Liver Institute at Methodist Dallas
Dallas, Texas, 75203
Liver Center of Texas
Dallas, Texas, 75234
GI Alliance - Texas Digestive Disease Consultants - Fort Worth - Downtown
Dallas, Texas, 75246
Southeast Clinical Research Center
Dalton, Georgia, 30720
Digestive Specialists - Dayton
Dayton, Ohio, 45414
Soma Clinical Trials
Denison, Texas, 75020
Henry Ford Health System
Detroit, Michigan, 48202
Digestive Health Specialist of the Southeast
Dothan, Alabama, 36305
Lone Peak Family Health
Draper, Utah, 84020
Physicians' Research Options LLC - Draper UT/Lone Peak Family Clinic
Draper, Utah, 84020
Ohio Gastroenterology Group, Inc. - Olentangy Office
Dublin, Ohio, 43016
Duke University Medical Center
Durham, North Carolina, 27710
Icahn School of Medicine at Mount Sinai
Durham, North Carolina, 27710
South Texas Research Institute - Edinburg
Edinburg, Texas, 78539
TriWest Research Associates
El Cajon, California, 92020
South Denver Gastroenterology - Swedish Medical Center Office
Englewood, Colorado, 80113
NECCR Prima Care Research, LLC
Fall River, Massachusetts, 02721
Cumberland Research Associates
Fayetteville, North Carolina, 28304
Gastrointestinal Associates & Endoscopy Center - Flowood
Flowood, Mississippi, 39232
Care United Medical Center - Forney
Forney, Texas, 75126
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Cure Clinical Research, LLC
Fountain Valley, California, 92708
SC Clinical Research
Garden Grove, California, 92844
Velocity Clinical Research - Gardena
Gardena, California, 90247
Digestive Health Associates of Texas - Rockwall
Garland, Texas, 75044
Gastro One - Germantown Office - Wolf Park Drive
Germantown, Tennessee, 38138
Mid-Atlantic GI Research
Greenbelt, Maryland, 20770
Carolina Digestive Diseases
Greenville, North Carolina, 27834
Meritus Center for Clinical Research
Hagerstown, Maryland, 21742
ASHA Clinical Research - Munster
Hammond, Indiana, 46324
Doral Medical Research, LLC
Hialeah, Florida, 33016
Palmetto Research
Hialeah, Florida, 33016
Tandem Clinical Research GI
Houma, Louisiana, 70363
Houston Methodist Hospital
Houston, Texas, 77030
Liver Associates of Texas
Houston, Texas, 77030
Liver Specialists of Texas
Houston, Texas, 77030
Houston Research Institute (HRI)
Houston, Texas, 77079
Pioneer Research Solutions
Houston, Texas, 77099
National Research Institute - Santa Ana
Huntington Park, California, 92704
Grand Teton Research Group, PLLC
Idaho Falls, Idaho, 83404
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
Arizona Digestive Health - Sun City
Kansas City, Kansas, 66160
University of Kansas Medical Center Research Institute
Kansas City, Kansas, 66160
Kansas City Research Institute
Kansas City, Missouri, 64131
Combined Gastro Research LLC
Lafayette, Louisiana, 70503
Florida Research Institute
Lakewood Rch, Florida, 34211
The Clinical Trials Network - Gastro Care Institute
Lancaster, California, 93534
Sierra Clinical Research - Las Vegas
Las Vegas, Nevada, 89106
Emeritas Research Group
Leesburg, Virginia, 20176
Galenus Group
Lehigh Acres, Florida, 33936
University of Kentucky
Lexington, Kentucky, 40506-0032
ARcare Center for Clinical Research
Little Rock, Arkansas, 72205
Arkansas Diagnostic Center
Little Rock, Arkansas, 72205
Summit - Pinnacle Clinical Research - Austin
Live Oak, Texas, 78233
National Research Institute - Westlake
Los Angeles, California, 90057
GI Alliance - Lubbock Digestive Disease Associates - Lubbock
Lubbock, Texas, 79410
North Alabama GI Research Center llc
Madison, Alabama, 60602
Accel Research Sites
Maitland, Florida, 32751
Centor for Advanced Gastroenterology - Main Office - Maitland
Maitland, Florida, 32751
Topography Health, Inc.
Manassas, Virginia, 20110
GI Alliance - Mansfield
Mansfield, Texas, 76063
Tandem Clinical Research
Marrero, Louisiana, 70072
Koncord Research - McAllen LLC
McAllen, Texas, 78504
Koncord Research-McAllen LLC
McAllen, Texas, 78504
Great Lakes Gastroenterology Research - Mentor
Mentor, Ohio, 44060
Metropolitan Gastroenterology Associates - Metairie
Metairie, Louisiana, 70006
Florida Vascular Research
Miami, Florida, 33012
Life Medical Research Group
Miami, Florida, 33122
Schiff Center for Liver Diseases
Miami, Florida, 33136
D&H National Research Centers
Miami, Florida, 33155
Future Care Solution
Miami, Florida, 33165
Genoma Research Group
Miami, Florida, 33165
Gastro Health - Galloway
Miami, Florida, 33173
Pro Live Medical Research
Miami, Florida, 33175
Miami Dade Medical Research Institute
Miami, Florida, 33176
Clinical Trials Services Corporation
Miami, Florida, 33181
Froedtert and Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
MNGI Digestive Health - Northeast Minneapolis Clinic
Minneapolis, Minnesota, 55413
Lucas Research, Inc
Morehead City, North Carolina, 28557
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
Yale School of Medicine
New Haven, Connecticut, 06520
Advanced Research Institute
New Port Richey, Florida, 34653
New York University Langone Gastroenterology Associates
New York, New York, 10016
Weill Cornell Medical College
New York, New York, 10021
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
Tandem Clinical Research - New York Clinic
New York, New York, 10033
Bon Secours Liver Institute of Hampton Roads
Newport News, Virginia, 23602
Digestive & Liver Disease Specialists
Norfolk, Virginia, 23502
Arkansas Gastroenterology
North Little Rock, Arkansas, 72117
Summit - Arkansas Gastroenterology
North Little Rock, Arkansas, 72117
Sensible Healthcare Clinical Research
Ocoee, Florida, 34761
AdventHealth Transplant Institute
Orlando, Florida, 32804
Digestive and Liver Center of Florida - Orlando
Orlando, Florida, 32825
IMIC Research - International Medical Investigations Centers
Palmetto Bay, Florida, 33157
National Research Institute - Panorama City
Panorama City, California, 91402
California Liver Reearch
Pasadena, California, 91105
American Research Centers of Florida
Pembroke Pines, Florida, 33027
Pensacola GI Research Center
Pensacola, Florida, 32503
Arizona Liver Health - Peoria
Peoria, Arizona, 85381
Dignity Health - St. Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Saint Joseph's Hospital and Medical Center
Phoenix, Arizona, 85013
Veterans Affairs Pittsburgh Healthcare System - University Drive Campus
Pittsburgh, Pennsylvania, 15240
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, 15261
Eminat, LLC
Plantation, Florida, 33317
D & H Pompano Research Center
Pompano Beach, Florida, 33064
NAPA Research
Pompano Beach, Florida, 33064
Cadena Care Institute
Poway, California, 92064
Rapid City Medical Center
Rapid City, South Dakota, 57701
Stanford University Medical Center
Redwood City, California, 94063
GI Select Health Research, LLC
Richmond, Virginia, 23236
Hunter Holmes Mcguire Veterans Affairs Medical Center - Richmond
Richmond, Virginia, 23249
Virginia Commonwealth University
Richmond, Virginia, 23284
Mayo Clinic - Rochester
Rochester, Minnesota, 55905
University of Rochester Medical Center
Rochester, New York, 14642
University of Utah School of Medicine
Salt Lake City, Utah, 84132
Quality Research - San Antonio
San Antonio, Texas, 78209
Sun Research Institute
San Antonio, Texas, 78215
Texas Liver Institute/American Research Corporation
San Antonio, Texas, 78215
University of California San Diego
San Antonio, Texas, 78215
Pinnacle Clinical Research - San Antonio
San Antonio, Texas, 78229
Research and Education, Inc.
San Diego, California, 92111
California Pacific Medical Center Research Institute
San Francisco, California, 64107
Quest Clinical Research
San Francisco, California, 94115
Silicon Valley Research Institute
San Jose, California, 95128
Covenant Metabolic Specialists LLC - Sarasota
Sarasota, Florida, 34420
Liver Institute Northwest
Seattle, Washington, 98105
Sherman Clinical Research
Sherman, Texas, 75092
Louisiana Research Center LLC
Shreveport, Louisiana, 71103
NorthShore University HealthSystem
Skokie, Illinois, 60077
Washington University School of Medicine in St. Louis
St Louis, Missouri, 63110
Richmond University Medical Center
Staten Island, New York, 10310
Olympus Clinical Research
Sugar Land, Texas, 77478
Palmetto Clinical Research
Summerville, South Carolina, 29485
Tampa General Hospital
Tampa, Florida, 33606
Clinical Trial Management Services
Thousand Oaks, California, 91360
Kansas Medical Clinic - Gastroenterology
Topeka, Kansas, 66606
Adobe Gastroenterology
Tucson, Arizona, 85712
Arizona Liver Health
Tucson, Arizona, 85712
Options Health Research
Tulsa, Oklahoma, 74104
San Fernando Valley Health Institute
Van Nuys, California, 91405
Impact Research Institute
Waco, Texas, 76710
Digestive Health Research of Central Texas
Waco, Texas, 76712
GI Alliance - Bay Area Gastroenterology - Webster
Webster, Texas, 77598
Clinovacare Medical Clinical Research Center
West Columbia, South Carolina, 29169
North Shore Gastroenterology
Westlake, Ohio, 44145
Cleveland Clinic Florida
Weston, Florida, 33331
Digestive Health Research of North Texas
Wichita Falls, Texas, 76301
Gastroenterology of the Piedmont, PA - Salem Office
Winston-Salem, North Carolina, 27103
Gastroenterology Associates of Western Michigan
Wyoming, Michigan, 49519
Florida Medical Clinic - Zephyrhills
Zephyrhills, Florida, 33542
China71 sites
Beijing Ditan Hospital Capital Medical University
Beijing, Beijing Municipality, 100010
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality
Peking University First Hospital
Beijing, Beijing Municipality
Peking University People's Hospital
Beijing, Beijing Municipality
Beijing You'an Hospital,Capital Medical University
Beijing, Fengtai
The First Hospital of Jilin University
Changchun
The Second Xiangya Hospital of Central South University
Changsha, Hunan, 410699
Xiangya Hospital - Central South University
Changsha
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
Chengdu, Sichuan Shi
West china hospital Sichuan University
Chengdu
Chongqing university three gorges hospital
Chongqing, Chongging
First Affiliated Hospital of the Army Military Medical University (Southwest Hospital)
Chongqing, Chongging
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality
The Second Affiliated Hospital of Chongqing Medical University
Chongqing
The First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian
Mengchao Hepatobiliary Hospital of FuJian Medical University
Fuzhou
Guangzhou First People's Hospital
Guangzhou, Guangdong
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong
The Eighth Affiliated Hospital,GuangZhou Medical University
Guangzhou, Guangdong
The First Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong
Guangdong Provincial people's hospital
Guangzhou
The Third Affiliated Hospital, Sun Yat-Sen University
Guangzhou
Guizhou Provincial People's Hospital
Guiyang, Guizhou
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou
The First Affiliated Hospital , Zhejiang University School of Medicine
Hangzhou, Zhejiang
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine - Qingchun Campus
Hangzhou
Heilongjiang Provincial Hospital
Harbin, Heilongjiang, 150036
Fourth Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, 230022
General Hospital of Tianjin Medical University
Heping
Qilu Hospital of Shandong University
Jinan, Shandong, 250012
The First People's Hospital of Yunnan Province
Kunming, Yunnan
The First Hospital of Lanzhou University
Lanzhou, Gansu
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, 210008
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu
The Second Hospital of Nanjing
Nanjing, Jiangsu
The First Affiliated Hospital of Guangxi Medical University
Nanning, Guangxi
Affiliated Hospital of Nantong University
Nantong, Jiangsu
Ningbo No.2 Hospital (Hwa Mei Hospital)
Ningbo
Qingdao Central Hospital
Qingdao, Shandong
Qingdao Municipal Hospital
Qingdao
RuiAn People's Hospital - Ruixiang Branch
Ruian, Zhejiang
Sanmenxia Central Hospital
Sanmenxia, Henan
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai
First Affiliated Hospital of China Medical University
Shenyang, Liaoning
The Sixth People' s Hospital Of ShenYang
Shenyang, Liaoning
Shengjing Hospital of China Medical University
Shenyang
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036
The University of Hong Kong-Shenzhen Hospital
Shenzhen
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050052
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu
Xu, Jun The First Hospital of Shanxi Medical University Taiyun Shanxi
Taiyuan, Shanxi
Tianjin Third Central Hospital
Tianjin
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei
Wuxi No.5 People's Hospital
Wuxi, Jiangsu
Xi'an International Medical Center
Xi'an, Shaanxi, 710126
Xi'an International Medical Center
Xi'an, Shaanxi
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi
The Third Affiliated Hospital Of Xinxiang Medical University
Xinxiang, Henan, 453000
Yiwu Central Hospital
Yiwu, Zhejiang, 322000
Yue Yang Central Hospital
Yueyang, Hunan, 414000
Henan Provincal People's Hospital
Zhengzhou, Henan
The Sixth People's Hospital of Zhengzhou
Zhengzhou, Henan
Zhengzhou First People's Hospital
Zhengzhou, Henan
The First Affiliated Hospital of Zhengzhou University
Zhengzhou
Zhengzhou People's Hospital
Zhengzhou
Third People's Hospital of Zhenjiang
Zhenjiang, Jiangsu
France27 sites
Centre Hosptitalier Universitaire d'Angers
Angers, Maine-et-Loire, 49933
Centre Hosptitalier Universitaire d'Angers
Angers, Maine-et-Loire
CHRU de Besançon - Hôpital Jean-Minjoz
Besançon, Franche-Comté, 25030
Centre Hospitalier Universitaire Estaing
Clermont-Ferrand, Puy-de-Dôme, 63003
Hôpitaux Universitaires Paris Nord Val-de-Seine - Hôpital Beaujon
Clichy, Île-de-France Region, 92118
Hôpitaux Universitaires Henri Mondor
Créteil, Île-de-France Region, 94000
CHU Dijon Bourgogne - Hôpital François Mitterrand
Dijon, Cantal
Centre Hospitalier Universitaire Grenoble Alpes
Grenoble, Isère, 38043
CHU de Lille - Hôpital Claude Huriez
Lille, Hauts-de-France, 59037
CHU de Limoges
Limoges, Limousin, 87042
Hôpital de la Croix Rousse
Lyon, Auvergne-Rhône-Alpes, 69317
Hôpital Saint-Joseph
Marseille, Bouches-du-Rhône, 13008
CHU Saint-Eloi
Montpellier, Occitanie, 34295
Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec
Nantes, Loire Atlantique, 44903
Centre Hospitalier Universitaire De Nantes - Hôpital Nord Laennec
Nantes, Nantes Cedex 1
Hôpital l'Archet
Nice, Provence-Alpes-Côte d'Azur Region, 06200
Hôpital Universitaire Pitié Salpêtrière
Paris, Île-de-France Region, 75013
Hôpital Saint-Antoine
Paris, Île-de-France Region, 75571
Hôpital Haut-Lévêque
Pessac, New Aquitaine, 33604
Hôpital Haut-Lévêque
Pessac, New Aquitaine
Centre Hospitalier Universitaire de Rennes
Rennes, Ille-et-Vilaine, 35033
Hôpital Hautepierre
Strasbourg, Bas-Rhin, 67200
Hôpital Rangueil
Toulouse, Occitanie, 31059
Clinique Pasteur
Toulouse, Occitanie, 31076
Hôpitaux de Brabois
Vandœuvre-lès-Nancy, Lorraine, 54511
Hôpitaux de Brabois
Vandœuvre-lès-Nancy, Lorraine
Hôpitaux Universitaires Paris-Sud - Hôpital Paul Brousse
Villejuif, Île-de-France Region, 94804
Spain19 sites
Complejo Hospitalario Torrecárdenas
Almería, Almería, 04009
Hospital Germans Trias i Pujol
Badalona, Badalona, 08916
Hospital de la Santa Creu i Sant Pau
Barcelona, Barcelona, 08025
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035
Hospital Universitari Vall d'Hebrón
Barcelona, Barcelona, 08035
Hospital Clínic de Barcelona
Barcelona, Barcelona, 08036
Complejo Asistencial Universitario de Leon
León, León, 24080
Hospital General Universitario Gregorio Marañón
Madrid, Madrid, 28007
Clínica Universidad de Navarra
Madrid, Madrid, 28027
Hospital Universitario Puerta de Hierro - Majadahonda
Majadahonda, Madrid, 28222
Hospital Universitario Son Espases
Palma de Mallorca, Balearic Islands, 07120
Complejo Hospitalario De Pontevedra
Pontevedra, Pontevedra, 36004
Consorci Corporació Sanitària Parc Taulí de Sabadell
Sabadell, Barcelona, 08208
Hospital Universitario Virgen del Rocío
Seville, Sevilla, 41011
Hospital Clínico Universitario de Valencia
Valencia, Valencia, 46010
Consorci Hospital General Universitari de València
Valencia, Valencia, 46014
Hospital Universitario Rio Hortega
Valladolid, Valladolid, 47012
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Zaragoza, 50009
Hospital Universitario Miguel Servet
Zaragoza, Zaragoza, 50009
Mexico18 sites
Centro de Investigación y Gastroenterología
Cuauhtémoc, Mexico City, 06700
PanAmerican Clinical Research Mexico - Cuernavaca
Cuernavaca, Morelos
Centro de Investigacion Medico Biologica y Terapia Avanzada
Guadalajara, Jalisco
Medical Care and Research S.A. de C.V.
Mérida, Yucatán, 97070
Consultorio de la Dra. Maria Sarai Gonzalez Huezo
Metepec
Instituto de Seguridad Social del Estado de Mexico y Municipios
Metepec
Oaxaca Site Management Organization S.C.
Metepec
Centro de Investigacion y Gastroenterologia, S.C.
Mexico City, Mexico City, 03330
Organismo Publico Descentralizado Hospital Juarez de Mexico
Mexico City, Mexico City, 7760
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ)
Mexico City
Investigacion Biomedica para el Desarrollo de Farmacos S.A. de C.V.
Mexico City
Investigaciones Medicas Cisneros
Monterrey, Nuevo León, 64000
Hospital Universitario Doctor José Eleuterio Gonzalez
Monterrey, Nuevo León, 64460
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" (Servicio de Gastroenterologia)
Monterrey
Hospital Universitario "Dr. José Eleuterio González" (Servicio de Endocrinología)
Monterrey
Hospital Universitario Dr. José Eleuterio González
Monterrey
Oaxaca Site Management Organization S.C.
Oaxaca City
Hospital Regional de Alta Especialidad de Zumpango
Zumpango
Germany12 sites
EPIMED
Berlin, State of Berlin, 10787
Gastroenterologie am Bayerischen Platz
Berlin, State of Berlin, 10825
Charité Universitätsmedizin Berlin
Berlin, State of Berlin, 13353
Klinikum Chemnitz
Chemnitz, Saxony, 09116
Uniklinik Köln
Cologne
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Saxony, 01307
Universitätsklinikum des Saarlandes
Homburg, Saarland, 66421
Eugastro
Leipzig, Saxony, 04103
Universitätsklinikum Schleswig-Holstein - Campus Lübeck
Lübeck, Schleswig-Holstein
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, Rhineland-Palatinate, 55131
Universitätsklinikum Düsseldorf
Northeim
St. Josefs-Hospital Wiesbaden
Wiesbaden, Hesse, 65189
United Kingdom12 sites
Panthera Biopartners - Glasgow
Glasgow, North Lanarkshire, G51 4TF
Barts Health NHS Trust
London, England, E1 1BB
Panthera Biopartners - North London
London, England, EN1 1LJ
King's College Hospital NHS Foundation Trust
London, England, SE5 9RS
Royal Free London NHS Foundation Trust
London
Panthera Biopartners - Manchester
Manchester, England, OL11 4AU
Panthera Biopartners - Manchester
Manchester, England
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, England, NE7 7DN
Nottingham University Hospitals NHS Trust
Nottingham, England
Panthera Biopartners - Preston
Preston, England, PR2 9QB
Sheffield Teaching Hospitals NHS FT
Sheffield, England
Royal Surrey County Hospital NHS Foundation Trust
Surrey Quays, England, GU2 7XX
Australia11 sites
Eastern Health - Australia
Box Hill, Victoria, 3128
Monash Medical Centre
Clayton, Victoria, 3168
Concord Repatriation General Hospital
Concord, New South Wales, 2139
Gallipoli Medical Research Foundation
Greenslopes, Queensland, 4120
Austin Health
Heidelberg, Victoria, 3084
Royal Brisbane and Women's Hospital
Herston, Queensland, 4029
Campbelltown Hospital
Liverpool, New South Wales, 2170
Liverpool Hospital
Liverpool, New South Wales, 2170
Fiona Stanley Hospital
Murdoch, Western Australia, 6150
Nepean Hospital
Penrith, New South Wales, 2750
Royal Perth Hospital
Perth, Western Australia, 6000
Poland11 sites
Synexus - Częstochowa
Częstochowa, Silesian Voivodeship, 42-202
Synexus Polska Sp. z o.o. Oddzial w Gdansku
Gdansk, 80-382
Synexus - Gdynia
Gdynia, Pomeranian Voivodeship, 81-537
Synexus - Katowice
Katowice, Silesian Voivodeship, 40-040
Centrum Medyczne Pratia - Katowice
Katowice, Silesian Voivodeship, 40-081
Synexus - Łódź
Lodz, Łódź Voivodeship, 90-127
ID Clinic
Mysłowice, Silesian Voivodeship, 41-400
Synexus - Poznań
Poznan, Greater Poland Voivodeship, 60-702
Synexus - Warszawa
Warsaw, Masovian Voivodeship, 01-192
Synexus - Wrocław
Wroclaw, Lower Silesian Voivodeship, 50-381
Niepubliczny Zaklad Opieki Zdrowotnej Centrum Badan Klinicznych
Wroclaw, Lower Silesian Voivodeship, 51-162
Belgium10 sites
Hôpital Erasme
Brussels, Brussels Capital, 1070
Cliniques Universitaires Saint-Luc
Brussels, Brussels Capital, 1200
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, 2650
Ziekenhuis Oost-Limburg - Campus Sint-Jan
Genk, Limburg, 3600
Algemeen Ziekenhuis Maria Middelares
Ghent, Oost-Vlaaderen, 9000
Universitair Ziekenhuis Gent
Ghent, Oost-Vlaanderen, 9000
Universitair Ziekenhuis Leuven - Campus Gasthuisberg
Leuven, Flemish Brabant, 3000
Centre Hospitalier Universitaire de Liège Site Sart Tilman
Liège, Liège, B-4000
Algemeen Ziekenhuis Delta - Campus Rumbeke
Roeselare, West-Vlaanderen, 8800
Vitaz
Sint-Niklaas, Oost-Vlaanderen, 9100
Italy10 sites
Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi
Bologna
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Milan, 20122
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Milan, 20162
Università degli Studi di Napoli Federico II
Naples, Napoli
Azienda Ospedaliero-Universitaria Maggiore della Carità di Novara
Novara, 28100
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Palermo, Palermo
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Roma
UOSD Interdipartimentale Degenza Medica a ciclo breve
Roma
Ospedale Casa Sollievo della Sofferenza
San Giovanni Rotondo, Foggia, 71013
Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino
Torino, 10126
Israel9 sites
Soroka Medical Center
Beersheba, Southern District, 84101
Rambam Health Care Campus
Haifa, Haifa District, 3109601
Carmel Medical Center
Haifa, Haifa District, 3436212
Shaare Zedek Medical Center
Jerusalem, Jerusalem, 9103102
Hadassah University Hospital Ein Kerem
Jerusalem, Jerusalem, 9112001
Western Galilee Hospital-Nahariya
Nahariya, Northern District, 22100
The Chaim Sheba Medical Center
Ramat Gan, Tel Aviv, 52621
Tel Aviv Sourasky Medical Center
Tel Aviv, Gush Dan, 64239
The Chaim Sheba Medical Center
Tel Aviv, Tel Aviv, 69710
Canada7 sites
William Osler Health System - Brampton Civic Hospital
Brampton, Ontario, L6R 3J7
Heritage Medical Research Centre
Calgary, Alberta, T2N 4Z6
St. Joseph's Healthcare Hamilton - Charlton Campus
Hamilton, Ontario, L8N 4A6
McGill University Health Centre
Montreal, Quebec, H4A 3J1
Centre de Médecine Métabolique de Lanaudière
Terrebonne, Quebec, J6X 497
University Health Network
Toronto, Ontario, M5G 2C4
Toronto Digestive Disease Associates
Vaughan, Ontario, L4L 4Y7
Argentina6 sites
Hospital De Alta Complejidad en Red El Cruce
Buenos Aires, Buenos Aires, C1124AAD
Hospital Británico de Buenos Aires
Buenos Aires, Buenos Aires, C1280AEB
Hospital Italiano de Buenos Aires
Ciudad Autónoma de Buenos Aires, Buenos Aires, C1199ABB
Hospital Italiano La Plata
La Plata, Buenos Aires, B1900AXI
Hospital Universitario Austral
Pilar, Buenos Aires, B1629AHJ
Hospital Provincial del Centenario
Rosario, Santa Fe Province, S2002KDS
Bulgaria6 sites
Acibadem City Clinic Tokuda Hospital
Sofia, Sofia, 1407
Diagnostic Consultative Center Aleksandrovska
Sofia, Sofia, 1431
Diagnostic Consulting Center 20 - Sofia Еооd
Sofia, Sofia, 1618
University Multiprofile Hospital for Active Treatment St. Ivan Rilski
Sofia, Sofia-Grad, 1431
University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov
Sofia, Sofia-Grad, 1612
Medical Center Medica Plus
Veliko Tarnovo, Veliko Tarnovo, 5006
Netherlands6 sites
Amsterdam Universitair Medische Centra - Vrije Universiteit Medisch Centrum
Amsterdam, North Holland, 1081 HV
Erasmus Medisch Centrum
Rotterdam, South Holland, 3015 GD
Franciscus Gasthuis & Vlietland
Rotterdam
Elisabeth-TweeSteden Ziekenhuis
Tilburg, North Brabant, 5000 LC
Ziekenhuis Bernhoven
Uden, North Brabent, 5400
Universitair Medisch Centrum Utrecht
Utrecht, Utrecht, 3584 CX
Portugal6 sites
Hospital de Braga
Braga, Braga District, 4710-243
Hospital da Senhora da Oliveira - Guimarães
Guimarães, Braga District, 4835-044
Centro Hospitalar Universitário Lisboa Norte - Hospital De Santa Maria
Lisbon, Lisbon District, 1649-035
Centro Hospitalar Universitário De São João
Porto, Porto District, 4200-319
Hospital Pedro Hispano
Senhora da Hora, Senhora Da Hora, Senhora Da Hora
Centro Hospitalar de Trás-Os-Montes e Alto-Douro - Hospital de S. Pedro
Vila Real, Vila Real District
South Africa6 sites
CTN (Clinical Trials Network): Somerset
Cape Town, Western Cape, 7130
Synexus - Mediclinic Southern Africa - Constantiaberg
Cape Town, Western Cape, 7800
Clinresco Centres
Kempton Park, Gauteng, 1619
Synexus Clinical Research SA- Watermeyer
Pretoria, Gauteng, 184
Synexus Clinical Research SA- Watermeyer
Pretoria, Pretoria, 0184
Synexus - Helderberg Clinical Research Centre - Somerset West
Somerset West, Western Cape, 7130
Brazil5 sites
Hospital das Clinicas da Universidade Federal de Minas Gerais
Belo Horizonte, Minas Gerais, 30130-100
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Cerqueira César, São Paulo, 05403-000
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, 90035-903
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto
Ribeirão Preto, São Paulo, 14051-140
Fundação Faculdade Regional de Medicina de São José do Rio Preto
São José do Rio Preto, São Paulo, 15090-000
Hungary5 sites
MIND Klinika
Budapest, Budapest, 1024
SYNEXUS Magyarország Egészségügyi Szolgáltató KFT
Budapest, Central Hungary, 1036
High Tech Medical Kft.
Budapest, 1064
Synexus Magyarország Egészségügyi Szolgáltató Kft. - Debrecen
Debrecen, Hajdú-Bihar, 4025
Debreceni Egyetem Klinikai Központ Kenézy Gyula Campus
Debrecen, Hajdú-Bihar, 4031
Chile3 sites
Hospital San Juan de Dios de La Serena
La Serena, Coquimbo Region, 1700000
Pontificia Universidad Católica de Chile - Escuela de Medicina
Santiago, Santiago Metropolitan, 8320000
Centro De Investigaciones Clínicas Viña Del Mar
Viña del Mar, Valparaiso, 2540364
Puerto Rico2 sites
Galenus Group of Pureto Rico
Manati, Pureto Rico, 00674
Fundación de Investigación de Diego Clinical Research
San Juan, Puerto Rico, 00927
Ukraine2 sites
Medical Center Medbud-Clinic, LLC
Kyiv, Kyiv Oblast, 3037
Medical Center Center of Family Medicine Plus, LLC
Kyiv, Kyiv Oblast, 4210
About this study
Official title: A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Read the detailed description
Primary objectives
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:
Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.
Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives
Key secondary objectives of Part 1:
- To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis
- To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH
Other secondary objectives of both Part 1 and Part 2:
- To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period)
- To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period)
- To assess the effect of lanifibranor on liver tests
- To assess the effect of lanifibranor on glycaemic parameters
- To assess the effect of lanifibranor on lipid parameters
- To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.
- To assess the effect of lanifibranor on health-related quality of life
- To assess the safety of lanifibranor
- To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Being tested
- IVA337, Placebo
- Keywords
- Phase III, Nonalcoholic Steatohepatitis, NASH, Peroxisome proliferator-activated receptor (PPAR), Liver Diseases, Fibrosis
- Medical subject headings
- Non-alcoholic Fatty Liver Disease, Liver Diseases, Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
IVA337Drug
Also called Lanifibranor
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
PlaceboDrug
A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
| Study group | Role | What they receive |
|---|---|---|
| Lanifibranor (IVA 337) (800 mg/day) | Experimental | 2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD) Receives: Drug: IVA337; Drug: Placebo |
| Lanifibranor (IVA 337) (1200 mg/day) | Experimental | 3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD) Receives: Drug: IVA337 |
| Matching placebo | Placebo comparator | 3 Placebo to match tablets with food --> once a day (quaque die, QD) Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resolution of NASH and improvement of fibrosis
Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline
Measured: Part A: Date of randomisation until the date of biopsy at Week 72
Safety Analyses
Part B: ATE:
- Using the DBPC on-treatment period, comparing the 2 active arms versus placebo
- Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.
Measured: 48 weeks after completion of DBPC period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Apr 2021
- Study start19 Aug 2021
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Sep 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for NASH - Nonalcoholic SteatohepatitisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Inventiva Pharma
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Arun J Sanyal, MD, Principal investigator, VCU Health, Gastroenterology Hepatology and Nutrition, 1200 West Broad Street, Richmond VA23298, USASven Francque, MD, Principal investigator, Division of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04849728
- Sponsor's protocol ID
- 337HNAS20011
- Acronym
- NATiV3
- Status last verified
- Mar 2026
- First submitted
- 16 Apr 2021
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3
- ClinicalTrials.gov ID
- NCT04849728
- Acronym / sponsor ID
- NATiV3 / 337HNAS20011
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Keywords
- Phase III, Nonalcoholic Steatohepatitis, NASH, Peroxisome proliferator-activated receptor (PPAR), Liver Diseases, Fibrosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Inventiva PharmaIndustry (pharma, biotech, devices)
- Study start
- 19 Aug 2021 (actual)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Sep 2027 (estimated)
- First posted
- 19 Apr 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Detailed description
Primary objectives
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:
Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.
Part B To assess the safety of lanifibranor beyond the DBPC period. Secondary objectives
Key secondary objectives of Part 1:
- To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis
- To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH
Other secondary objectives of both Part 1 and Part 2:
- To assess the effect of lanifibranor on other key histological features of NASH (only for DBPC period)
- To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period)
- To assess the effect of lanifibranor on liver tests
- To assess the effect of lanifibranor on glycaemic parameters
- To assess the effect of lanifibranor on lipid parameters
- To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.
- To assess the effect of lanifibranor on health-related quality of life
- To assess the safety of lanifibranor
- To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Lanifibranor (IVA 337) (800 mg/day) | Experimental | Drug: IVA337, Drug: Placebo2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD) |
| Lanifibranor (IVA 337) (1200 mg/day) | Experimental | Drug: IVA3373 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD) |
| Matching placebo | Placebo comparator | Drug: Placebo3 Placebo to match tablets with food --> once a day (quaque die, QD) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Male or female, aged ≥18 years at the time of signing informed consent
- Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):
- No qualitative change in dose for the drugs listed below:
- No qualitative change in dose for all other chronically administered drugs for at least 3 months prior to Screening
- Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)
Key exclusion criteria (30 listed)
- Documented causes of chronic liver disease other than NASH
- Histologically documented liver cirrhosis (fibrosis stage F4)
- History or current diagnosis of hepatocellular carcinoma (HCC)
- History of or planned liver transplant
- Positive human immunodeficiency virus (HIV) serology
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| IVA337Also: LanifibranorA total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B. | Drug | Lanifibranor (IVA 337) (1200 mg/day), Lanifibranor (IVA 337) (800 mg/day) |
| PlaceboA total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B. | Drug | Lanifibranor (IVA 337) (800 mg/day), Matching placebo |
Primary outcome
Resolution of NASH and improvement of fibrosis
Time frame: Part A: Date of randomisation until the date of biopsy at Week 72
Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline
Safety Analyses
Time frame: 48 weeks after completion of DBPC period
Part B: ATE: * Using the DBPC on-treatment period, comparing the 2 active arms versus placebo * Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
Related trials for NASH - Nonalcoholic Steatohepatitis
RecruitingPhase 2
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Recruiting
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) +Optimized Lifestyle Intervention (OLI) vs Sham + OLI for Weight Loss
Overweight and/or Obesity, Metabolic Syndrome
RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Enrolling by invitation
Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach
Obesity, Morbid, Metabolic Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Arun J Sanyal, MD principal investigator
VCU Health, Gastroenterology Hepatology and Nutrition, 1200 West Broad Street, Richmond VA23298, USA
Sven Francque, MD principal investigator
Division of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijkstraat 10, B-2650 Edegem, Belgium
459 sites in 24 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing IVA337 in people with NASH - Nonalcoholic Steatohepatitis, run by Inventiva Pharma at 459 sites in 24 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 459 sites in United States, China, France, Spain, Mexico and 19 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resolution of NASH and improvement of fibrosis (time frame: Part A: Date of randomisation until the date of biopsy at Week 72). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.